摘要
目的观察重组人促红细胞生成素联合放疗对消化道肿瘤的近期疗效和不良反应。方法 62例欲接受放疗的消化道肿瘤患者随机分为治疗组和对照组。治疗组患者在放疗一周前开始接受重组人促红细胞生成素注射液的治疗,每次10 000 IU,每周3次,皮下注射,直至放疗结束。对照组为单纯放疗,两组放疗方式均为三维适形调强放疗,6MV-X线,2 Gy·次-1,每周5次。结果放疗结束后3个月,治疗组、对照组的临床总有效率(RR)分别为96.8%、74.1%(P<0.05);在Ⅰ级和Ⅱ级血红蛋白减少方面,治疗组、对照组分别为0、61.3%和0、35.5%(P<0.05);在Ⅰ级血小板减少方面,治疗组、对照组分别为12.9%和38.1%(P<0.05)。在消化道反应、皮肤损伤和血压升高方面,无显著差异。结论重组人促红细胞生成素注射液联合放疗能提高消化道肿瘤的疗效,减少贫血的发生,值得进一步研究和应用。
AIM To analyze the recent curative effect and adverse reaction of recombinant human erythropoietin injection combined with radiotherapy in gastrointestinal tumor. METHODS Totally 62 patients with gastrointestinal tumor were randomly divided into treatment group and control group. The patients of the treatment group were given recombinant human erythropoietin injection, 10 000 IU each time, three times weekly, from one week before radiotherapy, until radiotherapy finished. The patients of the control group only received radiotherapy treatment. Intensity-modulated radiation therapy were used in both groups, 6 MV-X rays, 2 Gy each time, 5 times per week. Current curative effect, gastrointestinal reaction, bone marrow inhibition, skin response were observed. RESULTS The overall remission rate of the treatment group patients were significantly higher than the control group three months after radiotherapy, lower hemoglobin and thrombocytopenia decreased than the control group. The overall remission rates （RR） in the treatment group andcontrol group were 96.8% and 74.1% （P 〈 0.05） three months after radiotherapy. The incidence of grade Ⅰ and Ⅱ decreased hemoglobin of treatment group and control group was respectively 0, 61.3% and 0, 35.5% （P 〈 0.05）. The incidence of grade I decreased thrombocytopenia was respectively 12.9% and 38.1% （P 〈 0.05）. The reaction of gastrointestinal tract, skin damage, blood pressure elevation of two groups, had no significant difference. CONCLUSION Recombinant human erythropoietin injection combined with radiotherapy can improve curative effect in gastrointestinal tumor, reduce the occurrence of reduced hemoglobin and thrombocytopenia, deserves further research and application.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2014年第12期890-893,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
红细胞生成素
重组
放射疗法
肿瘤
erythropoietin recombinant
radiotherapy
neoplasms
